Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.
about
Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute LeukemiaGenetics of ancestry-specific risk for relapse in acute lymphoblastic leukemiaGermline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study.Investigating CD99 Expression in Leukemia Propagating Cells in Childhood T Cell Acute Lymphoblastic Leukemia.A retrospective analysis of treatment-related hospitalization costs of pediatric, adolescent, and young adult acute lymphoblastic leukemiaClinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia.Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis.Immunophenotyping by Multiparameter Flow Cytometry.Relapse of childhood acute lymphoblastic leukemia and outcomes at a reference center in Latin America: organomegaly at diagnosis is a significant clinical predictor.Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group.Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children.Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.Imaging of primary pediatric lymphoma of bone.A QA program for MRD testing demonstrates that systematic education can reduce discordance among experienced interpreters.A bright and colorful future for DNA cell cycle analysis.Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances.Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.Novel therapy for childhood acute lymphoblastic leukemia.When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia.Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.Qualitative polymerase chain reaction versus quantitative polymerase chain reaction for the detection of minimal residual disease in children with acute lymphoblastic leukemia.Flow cytometric analysis of CD64 expression pattern and density in the diagnosis of acute promyelocytic leukemia: a multi-center study in Shanghai, China.Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.Recent advances in the management of pediatric acute lymphoblastic leukemia.Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens.Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing.Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.Blinatumomab activity in a patient with Down syndrome B-precursor acute lymphoblastic leukemia.Agents in Development for Childhood Acute Lymphoblastic Leukemia.CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia.Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.
P2860
Q26781328-C857E38A-FDC0-4EEE-AF5A-5BB970BA9B80Q33774499-84FF52F0-4ADB-425E-8935-C8103048C0C1Q34500075-42A476B5-D281-4B18-A596-2E05A1A19347Q36169572-26639C25-D5F2-406B-A28F-D2549B1D9D1BQ36528384-8782F3FA-5AAE-405D-B5B1-43FB2B0040B1Q37130123-12C113E1-72A2-4171-B077-C31DA5ED9415Q37169331-03C5756B-AC79-4C01-8B20-70DE44666D3DQ37619915-5A59235F-87DE-469C-8189-5C32AD3C1E93Q37624584-D2BEBBC6-E18D-4543-8216-99CE2AA11469Q38630532-AD601053-58E4-4370-94D4-C173B65ACCD9Q38666234-76094F64-1D55-4450-B8D9-8A941DCF2F92Q38744187-AD5A4217-CD33-43C1-922A-C7D97C57BC6FQ38749564-4DF0B8EB-B0F8-4F3D-A8E0-CE6305AB47BFQ38769075-92FB2CEB-272D-4B75-B5A4-A5057F08EEE0Q38782141-90D6D11C-752D-4CE1-8046-3213FF137C64Q38792016-A9DA9CBA-48F9-4F99-A2E8-4702C30EDC94Q38797810-42FF3B1D-893C-4F39-82C6-8BE57100AB41Q38802404-84CAA372-6321-4B64-B7C2-1D82A9377171Q38909582-6215A330-BAA9-4C87-864D-D0AC0BA129DEQ38922016-16ED31C9-D592-42BF-BA5C-744B0C6327D4Q39041475-5423FE5F-8BC4-4532-AEA0-904F2BA63DFEQ39123286-FC28EF2C-5979-4AFE-9282-0308011AAE83Q39285841-B7C47291-819E-4416-B4FB-7A78D9903C32Q39368957-8AE10A4A-2AB9-4DA0-ACA7-0280A79BDC75Q39420711-AC06ED10-6280-4CA2-910C-2F2A598A7FE1Q40312849-08D5EBDD-E6E9-40EC-A8DE-6EB7A86C0F85Q41893098-2C23716F-05A5-4E5B-B10A-64A302896C5EQ43258471-78829DCC-8484-4337-809B-AED2D3CC1E46Q45066985-69E46CFB-C8F1-4C4F-9224-57032A4FFB53Q45105040-CDDB20C8-6976-49F6-8FC0-C2BEB1D79309Q45985775-5531C7B0-6A68-4C9D-BDB1-654E5E1EEC3CQ46103668-F2F2B970-D5F7-484F-AC49-1F725F8B6D5EQ46711660-6E01C95D-4FB0-4AA7-8836-68CF3E6FC1D6Q47786126-3263F406-42F3-4D4E-8AA4-DE56EAB40555Q47837260-B080C870-0B94-4011-9255-EB79FA6B5171Q48272279-7F2273E3-D4B6-4A1D-B877-67B1AD259FC1Q48369402-508AF7D3-0D66-4C53-94D0-D97F46ED4B7AQ49332440-9E60EE82-781A-4231-B933-BB8165028953Q49988832-B4BFC76D-EEF5-49A9-BA3D-7FB1E1E17D83Q50209854-065BBA8C-2A70-46D7-82B3-22A3A40F9605
P2860
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Prognostic significance of min ...... Oncology Group study AALL0232.
@ast
Prognostic significance of min ...... Oncology Group study AALL0232.
@en
type
label
Prognostic significance of min ...... Oncology Group study AALL0232.
@ast
Prognostic significance of min ...... Oncology Group study AALL0232.
@en
prefLabel
Prognostic significance of min ...... Oncology Group study AALL0232.
@ast
Prognostic significance of min ...... Oncology Group study AALL0232.
@en
P2093
P2860
P1433
P1476
Prognostic significance of min ...... Oncology Group study AALL0232.
@en
P2093
Andrew J Carroll
Brent L Wood
Cheryl L Willman
Elizabeth A Raetz
Eric Larsen
James B Nachman
Julie M Gastier-Foster
Meenakshi Devidas
Michael J Borowitz
Mignon L Loh
P2860
P304
P356
10.1182/BLOOD-2015-03-633685
P407
P577
2015-06-29T00:00:00Z